Skip to main content
. 2017 Sep 19;108(11):2265–2272. doi: 10.1111/cas.13386

Figure 4.

Figure 4

Combination treatment with sorafenib (SOR) and betulinic acid (BA) is not toxic to human peripheral blood lymphocytes (PBL). (a) Cell viability of PBL cells after treatment with sorafenib 1.3 μg/mL and betulinic acid 3 μg/mL alone and in combination (n = 4). Data are presented as means ± SD normalized to untreated control. (b) Representative Annexin V‐FITC/PI‐double staining histograms of PBL cells after treatments with 1.3 μg/mL sorafenib and 3 μg/mL betulinic acid alone and in combination (n = 3). *P < 0.05, **P < 0.01 compared with sorafenib treatment group and betulinic acid treatment group.